RORs were chosen as molecular targets because these receptor proteins are an attractive but not extensively studied family of potential drug targets. They constitute a family of ligand-activated transcription factors that mainly act as monomers involved in the circadian control of energy homeostasis and immune system regulation , among other functions. RORs hold promising pharmacological potential for various indications, specifically for autoimmune diseases . No ROR ligand has reached drug approval to date, partially owing to compound-related issues such as poor aqueous solubility, lack of selectivity, and clinical safety concerns .